| Name | Title | Contact Details |
|---|
Modern Medical is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Modern Medical is based in Lewis Center, OH. You can find more information on Modern Medical at www.modernmedical.com
Medical Center at Franklin is a Franklin, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Southern Medical Inc is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
American Pathology Partners (AP2) company career center! We appreciate your interest in career opportunities with us and encourage you to explore our site to learn more about us and our partner laboratories in Colorado (UniPath), Florida (Palm Beach Pathology), North Carolina (Eastern Carolina Pathology). We are committed to building long-term partnerships within the communities we serve through service excellence and our commitment to the latest in technological innovation. Our pathologist partners are valued leaders within our affiliated laboratories and deliver specialized anatomic and molecular pathology services within their local and regional healthcare markets. As a growing organization, we offer a diversity of laboratory positions in histology, grossing, flow cytometry, cytology processing, molecular as well as career opportunities in finance, sales, information technology and human resources. We offer a competitive salary and excellent benefits package including Medical, Dental, Vision, Life, Long-Term Disability, Flexible Spending Accounts, and a Tuition Reimbursement Program. In addition, we support ongoing educational programs and career opportunities; provide liberal Paid Time Off benefits; and offer a generous Retirement 401(k) plan.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.